Allosteros Therapeutics, Inc. was a drug discovery company developing novel, potent, and selective small molecule of a critical signaling pathway that promotes heart disease. Inhibitors of a Ca2+-dependent protein kinase called CaMKII show positive preclinical proof of concept in atrial fibrillation and ventricular arrhythmia by normalizing Ca2+ homeostasis that also underlies heart failure. The company was founded in 2010 by pioneering scientists, Drs. Howard Schulman (CEO and CSO) and Mark Anderson (Head of Medicine, Johns Hopkins; Advisor). They have progressed with capital efficiency toward candidate selection and plan stepwise development of CaMKII inhibitors for several cardiovascular indications with venture capital and pharma partners.
